A Draft Revision on the “Regulations on Functional Cosmetics Review”

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020
The Ministry of Food and Drug Safety (MFDS) of the Republic of Korea is partly revising the “Regulations on Functional Cosmetics Review” (Public Notice issued by the MFDS) for the following purposes: a) to reflect the revised scope of atopy-related functional cosmetics in the “Enforcement Rule of the Cosmetics Act,” (August 2020) which is the superior law, allow human trials on cosmetics for atopy to be conducted by “laboratories for human trials” as for other functional cosmetics b) to record of side effects and actions taken in the human trial of functional cosmetics in accordance with the provision on human trials in the “Regulation on Substantiation of Claims in Labeling or Advertising of Cosmetic Products”; c) to provide a legal ground for partial exemption of data submission for the review of the “cosmetics that help relieve hair loss symptoms” under Article 2 subparagraph 8 of the “Enforcement Rules of the Cosmetics Act”; d) to revise terminology (e.g. responsible cosmetic seller) and references to provisions in accordance with the changes in other relevant regulations
Products Covered: Cosmetics
Regulation Type: Regular notification
Establishment of the Japanese Pharmacopoeia Eighteenth edition

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020
Ministry of Health and Labour and Welfare will abolish the Japanese Pharmacopoeia Seventeenth edition and establish Eighteenth edition under Paragraph 1 of Article 41 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Japanese Pharmacopoeia, Seventeenth edition are to be revised.
Products Covered: Pharmaceutical Products (HS:30)
Regulation Type: Regular notification
Establishment of the Japanese Pharmacopoeia Eighteenth edition

Distribution date: 22 October 2020 | Final date for Comment: 21 December 2020
Ministry of Health and Labour and Welfare will abolish the Japanese Pharmacopoeia Seventeenth edition and establish Eighteenth edition under Paragraph 1 of Article 41 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Japanese Pharmacopoeia, Seventeenth edition are to be revised.
Products Covered: Pharmaceutical Products (HS:30)
Regulation Type: Regular notification
Update of Annex I of the Collegiate Board Resolution - RDC No. 405 of 22 July 2020

Distribution date: 20 October 2020
The Annex I of the Resolution – RDC number 405, 22 July 2020 – previously notified through G/TBT/N/BRA/1061 – which establishes control measures for medicines that contain substances mentioned by the Annex I of this resolution, isolated or in association with other drugs, due to the international public health emergency of the new coronavirus (SARS-CoV-2), was changed by the Resolution – RDC number 420, 1 September 2020.
Products Covered:
Regulation Type: Addendum to Regular Notification
Update of Annex I of the Collegiate Board Resolution - RDC No. 405 of 22 July 2020

Distribution date: 20 October 2020
The Annex I of the Resolution – RDC number 405, 22 July 2020 – previously notified through G/TBT/N/BRA/1061 – which establishes control measures for medicines that contain substances mentioned by the Annex I of this resolution, isolated or in association with other drugs, due to the international public health emergency of the new coronavirus (SARS-CoV-2), was changed by the Resolution – RDC number 420, 1 September 2020.
Products Covered:
Regulation Type: Addendum to Regular Notification
(1) Partial amendment to the Minimum Requirements for Biological Products (2) Partial amendment to the Public Notice on National Release Testing

Distribution date: 20 October 2020 | Final date for Comment: 19 November 2020
(1) The Minimum Requirements for Biological Products shall be partially amended to add the standard for a blood product to be newly approved. (2) The Public Notice on National Release Testing shall be partially amended to provide for the above-mentioned blood product.
Products Covered: Pharmaceutical Products (HS: 30)
Regulation Type: Regular notification
(1) Partial amendment to the Minimum Requirements for Biological Products (2) Partial amendment to the Public Notice on National Release Testing

Distribution date: 20 October 2020 | Final date for Comment: 19 November 2020
(1) The Minimum Requirements for Biological Products shall be partially amended to add the standard for a blood product to be newly approved. (2) The Public Notice on National Release Testing shall be partially amended to provide for the above-mentioned blood product.
Products Covered: Pharmaceutical Products (HS: 30)
Regulation Type: Regular notification
A draft revision of “Pharmaceutical Affairs Act”

Distribution date: 20 October 2020 | Final date for Comment: 19 December 2020
The Ministry of Food and Drug Safety of the Republic of Korea is partly revising the “Pharmaceutical Affairs Act”. The main contents are: For the pharmaceutical imported, similar to pharmaceutical manufactured, the distribution has been managed thoroughly by prescribing the prohibition another pharmaceutical that is not identical with the approved and reported information such as ingredient and amount from importing, storing and displaying for the purpose of marketing. Under “Safety Control Act of Household Chemicals and Biocidal Product” (Established on 20 Mar 2018; Implemented on 1 Jan 2019), the managing body shall be excluded in the scope of quasi-drug as nematicide and humidifier disinfectant of fly and mosquito that were controlled as quasi-drug according to “Pharmaceutical Affairs Act” was changed. (Article 2, 62 and 68-4)
Products Covered: Pharmaceuticals, Quasi-drug
Regulation Type: Regular notification
A draft revision of “Pharmaceutical Affairs Act”

Distribution date: 20 October 2020 | Final date for Comment: 19 December 2020
The Ministry of Food and Drug Safety of the Republic of Korea is partly revising the “Pharmaceutical Affairs Act”. The main contents are: For the pharmaceutical imported, similar to pharmaceutical manufactured, the distribution has been managed thoroughly by prescribing the prohibition another pharmaceutical that is not identical with the approved and reported information such as ingredient and amount from importing, storing and displaying for the purpose of marketing. Under “Safety Control Act of Household Chemicals and Biocidal Product” (Established on 20 Mar 2018; Implemented on 1 Jan 2019), the managing body shall be excluded in the scope of quasi-drug as nematicide and humidifier disinfectant of fly and mosquito that were controlled as quasi-drug according to “Pharmaceutical Affairs Act” was changed. (Article 2, 62 and 68-4)
Products Covered: Pharmaceuticals, Quasi-drug
Regulation Type: Regular notification
Normative Instruction number 73, 1 September 2020

Distribution date: 19 October 2020
This Normative Instruction establishes the inclusion of a declaration in the label of pesticides informing the existence of a new formula changing its composition. This regulation will be also notified to the SPS committee.
Products Covered: HS Code(s): 38089910 (pesticides)
Regulation Type: Regular notification
Submit your email ID to receive notifications about upcoming courses and events